HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HKPD
Cellyan Biotechnology Co., Ltd
There isn't enough reported data to score HKPD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HKPD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate HKPD's fundamentals.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HKPD PE Valuation
HKPD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HKPD Forward outlook
There aren't enough analyst estimates for HKPD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HKPD Earnings Per Share
HKPD and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HKPD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HKPD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $6.3M | -32% |
| Q3 2025 | $7.1M | -36% |
| Q1 2025 | $9.2M | -4.7% |
| Q3 2024 | $11.1M | +58% |
HIMS has the edge over HKPD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -20% | -33 points |
| Q3 2025 | -9.8% | -14 points |
| Q1 2025 | -9.7% | N/A |
| Q3 2024 | 9.3% | N/A |
| Q1 2024 | 13% | N/A |
| Q3 2023 | 4.4% | N/A |
HKPD's operating margin was −20% last quarter, down 33 points from the same quarter a year ago, near the bottom of its range since 2023.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
HKPD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$507.6K | -$294.8K |
| Q3 2025 | -$279.5K | -139% |
| Q1 2025 | -$212.8K | +$98.6K |
| Q3 2024 | $712.1K | +$847.7K |
HKPD and HIMS do not have enough comparable growth data to identify a winner.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HKPD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HKPD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +227% | +1.2M shares |
| 1 year | +260% | +1.3M shares |
HKPD has 2M diluted shares, up 260% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q1 2024 | — |
| Q3 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HKPD Net Leverage
HKPD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HKPD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.4 | Oversold |
| Stochastic | 2.8 | Oversold |
HKPD's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HKPD PE vs Healthcare Sector
HKPD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HKPD has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus HKPD above 0 of 3.
HKPD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.98 | 23% below |
| 20 week MA | $4.83 | 68% below |
| 50 week MA | $9.83 | 84% below |
HKPD is in a downtrend: it's below all three of its weekly moving averages, and 84% below its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over HKPD on returns for 2026, with the stronger performance.
HKPD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $55.0 | $15.9 | -71% |
| 2026 YTD | $15.9 | $1.53 | -90% |
HKPD has finished every year since 2025 lower, and it's down 90% so far in 2026.